journal
https://read.qxmd.com/read/38653647/the-introduction-of-magtrace%C3%A2-lymphatic-tracer-for-axillary-sentinel-node-biopsy-for-breast-cancer-in-a-rural-scottish-district-general-hospital-initial-experience-perspectives-outcomes-and-learning-curves
#1
JOURNAL ARTICLE
Chia Yew Kong, Jacob Williams, Niroshini Hemadasa, Dermot Murphy, Maria Bews-Hair
BACKGROUND: Magtrace is a supraparamagnetic iron lymphatic tracer that has had increasing use in sentinel node biopsy (SNB) for breast cancer and has theoretical logistical benefits in centres where nanocolloid use may be associated with such issues. We describe our initial experience with the introduction of Magtrace into our routine practice by dual localisation with nanocolloid, comparing performance, and concordance. MATERIALS AND METHODS: This was prospective study of the first patients undergoing axillary SNB using Magtrace in a single centre...
March 30, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38627193/existing-psychiatric-diagnoses-among-breast-cancer-patients-interact-with-outcomes-after-autologous-and-implant-based-bilateral-breast-reconstruction-a-propensity-score-matched-analysis
#2
JOURNAL ARTICLE
George S Corpuz, Dylan K Kim, Isaac E Kim, Christine H Rohde
BACKGROUND: Breast reconstruction is an integral postoncologic procedure that has been associated with improved mental health and psychological outcomes. The possible interaction between existing psychiatric diagnoses hospital courses and postoperative complications warrants further exploration. METHODS: Bilateral breast reconstruction patients were identified from the 2016 to 2018 Healthcare Cost and Utilization Project-National Inpatient Sample (HCUP - NIS). Number and type of psychiatric diagnoses within the cohort were then evaluated using a host of ICD-10 codes...
March 24, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38627192/development-of-an-ultrasound-based-nomogram-for-predicting-pathologic-complete-response-and-axillary-response-in-node-positive-patients-with-triple-negative-breast-cancer
#3
JOURNAL ARTICLE
Manqi Zhang, Hailing Zha, Jiazhen Pan, Xiaoan Liu, Min Zong, Liwen Du, Yu Du
BACKGROUND: The accurate prediction of pathological complete response (pCR) in the breast and axillary lymph nodes (ALN) before neoadjuvant chemotherapy (NAC) is of utmost importance for the development of treatment strategies. We aim to construct a nomogram on ultrasound (US) and clinical-pathologic factors to predict breast and ALN pCR in node-positive triple-negative breast cancers (TNBCs). METHODS: Patients identified with TNBCs from institution 1 (n = 328) were used for training cohort and those from institution 2 (n = 192) were for validation cohort...
March 23, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38609794/comparison-of-clinical-breast-exam-to-breast-mri-surveillance-in-patients-following-nipple-sparing-mastectomy
#4
JOURNAL ARTICLE
Christina Weed, Ton Wang, Srivarshini C Mohan, Xuanji Wang, Joshua Tseng, Theodore Hu, Jutla Jaswinder, Marissa K Boyle, Farin Amersi, Armando Giuliano, Alice Chung
BACKGROUND: Nipple sparing mastectomy (NSM) is increasingly being performed for patients with breast cancer. However, optimal postoperative surveillance has not been defined. METHODS: A prospectively maintained database identified patients with in-situ and invasive cancer who underwent NSM between 2007-2021. Clinical data on postoperative breast surveillance and interventions were collected. Patients who had MRI surveillance versus clinical breast exam (CBE) alone were compared with respect to tumor characteristics, recurrence, and survival...
March 20, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38641470/the-fgfr2-variant-rs13387042-is-associated-with-breast-cancer-risk-a-meta-analysis-and-systematic-review
#5
JOURNAL ARTICLE
Weining Pan, Hui Cheng, Juan Zhang, Zijie Yang, Mengbo Lin
OBJECTIVE: The association of FGFR2-rs13387042 polymorphism with breast cancer (BC) susceptibility in women remains inconclusive due to varying reports. In this study, we conducted a meta-analysis to explore the relationship between FGFR2-rs13387042 polymorphism and susceptibility to BC. METHODS: Relevant literature were acquired through searches across multiple databases. Odds ratio (OR) values were pooled to assess the risk of BC for different alleles and genotypes...
March 15, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38616444/plasma-thioredoxin-reductase-as-a-potential-diagnostic-biomarker-for-breast-cancer
#6
JOURNAL ARTICLE
Yixuan Hu, Yinxing Zhu, Junfeng Shi, Xiaowei Wei, Cuiju Tang, Xiaoxiang Guan, Wenwen Zhang
BACKGROUND: Early diagnosis of breast cancer is critical to the treatment and prognosis of breast cancer patients. Our aim is to explore more practical and effective diagnostic methods to facilitate early treatment and improve prognosis for breast cancer patients. MATERIALS AND METHODS: The Mann-Whitney U test, receiver operating characteristic curve, Youden index, Chi-square test, and Fisher's exact test were used to determine whether plasma thioredoxin reductase (TrxR) could be used for the clinical diagnosis of breast cancer...
March 15, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38614852/hypofractionation-for-regional-nodal-irradiation-in-breast-cancer-best-of-both-the-worlds
#7
REVIEW
Budhi Singh Yadav, Treshita Dey
Locoregional radiotherapy play an important role in controlling the disease after surgery in patients with breast cancer. Radiotherapy schedules vary from conventional fraction to hypofractionation. The purpose of this review is to get an insight into the data on regional nodal irradiation (RNI) with hypofractionation in patients with breast cancer. This systematic review was constructed in accordance with Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) framework. Electronic databases such as PubMed, Cochrane and EMBASE were searched from January 1, 2023 to March 31, 2023 to identify studies published in English language on hypofractionated RNI in post mastectomy patients...
March 14, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38616443/systemic-therapy-advances-for-her2-positive-and-triple-negative-breast-cancer-what-the-surgeon-needs-to-know
#8
REVIEW
Stephanie Downs-Canner, Anna Weiss
Neoadjuvant systemic therapy (NST) was initially reserved for unresectable patients however it has been increasingly used to facilitate breast conservation, downstage the axilla, and inform adjuvant therapy decisions based on response. For patients with HER2+ and triple-negative breast cancer (TNBC), clinical trials have resulted in the ability to individualize treatment regimens. For HER2+ breast cancer, de-escalation of neoadjuvant regimens to minimize cytotoxic chemotherapy and de-escalation or escalation of adjuvant regimens based on response have been effective...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38580573/nomogram-based-on-us-and-clinicopathologic-characteristics-axillary-nodal-evaluation-following-neoadjuvant-chemotherapy-in-patients-with-node-positive-breast-cancer
#9
JOURNAL ARTICLE
Jia-Xin Huang, Yi-Jie Chen, Xue-Yan Wang, Jia-Hui Huang, Ke-Hong Gan, Li-Na Tang, Xiao-Qing Pei
BACKGROUND: To develop a convenient modality to predict axillary response to neoadjuvant chemotherapy (NAC) in breast cancer patients. MATERIALS AND METHODS: In this multi-center study, a total of 1019 breast cancer patients with biopsy-proven positive lymph node (LN) receiving NAC were randomly assigned to the training and validation groups at a ratio of 7:3. Clinicopathologic and ultrasound (US) characteristics of both primary tumors and LNs were used to develop corresponding prediction models, and a nomogram integrating clinicopathologic and US predictors was generated to predict the axillary response to NAC...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38555225/combination-of-dce-mri-and-nme-dwi-via-deep-neural-network-for-predicting-breast-cancer-molecular-subtypes
#10
JOURNAL ARTICLE
Zhi-Chang Ba, Hong-Xia Zhang, Ao-Yu Liu, Xin-Xiang Zhou, Lu Liu, Xin-Yi Wang, Abiyasi Nanding, Xi-Qiao Sang, Zi-Xiang Kuai
BACKGROUND: To explore whether the combination of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and nonmono-exponential (NME) model-based diffusion-weighted imaging (DWI) via deep neural network (DNN) can improve the prediction of breast cancer molecular subtypes compared to either imaging technique used alone. PATIENTS AND METHODS: This prospective study examined 480 breast cancers in 475 patients undergoing DCE-MRI and NME-DWI at 3.0 T. Breast cancers were classified as follows: human epidermal growth factor receptor 2 enriched (HER2-enriched), luminal A, luminal B (HER2-), luminal B (HER2+), and triple-negative subtypes...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38582616/is-immediate-breast-reconstruction-with-a-latissimus-dorsi-myocutaneous-flap-safe-for-starting-adjuvant-chemotherapy-in-patients-with-breast-cancer
#11
JOURNAL ARTICLE
Gabriel Salum D'Alessandro, Alexandre Mendonça Munhoz, Fabiana Midori Takeuchi, Alejandro Povedano, João Carlos Sampaio Goes
INTRODUCTION: Immediate breast reconstruction following mastectomy reduces perceptions of mutilation and femininity issues in oncological patients, but surgical complications should not delay chemotherapy. This study evaluated postsurgical complications in patients who underwent radical breast surgery followed by immediate reconstruction with latissimus dorsi myocutaneous flaps and silicone implants, along with resulting impacts in delaying chemotherapy. MATERIALS AND METHODS: This retrospective study utilized a prospectively maintained database...
March 10, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38582617/the-role-of-immunotherapy-in-triple-negative-breast-cancer-tnbc
#12
REVIEW
Elena Michaels, Nan Chen, Rita Nanda
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. Our understanding of the heterogeneity of TNBC has increased over the past decade, and with it a recognition that some TNBCs are immunogenically active. This finding has led to the investigation of immunotherapy-based approaches for treatment of both early and advanced-stage TNBC. In this review, we provide an overview of the biologic rationale for immunotherapy use in TNBC, and review data from seminal trials which have culminated in the approval of immunotherapy for both early and advanced TNBC...
March 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38553373/expression-and-clinical-significance-of-nudcd1-pi3k-akt-mtor-signaling-pathway-related-molecules-and-immune-infiltration-in-breast-cancer
#13
JOURNAL ARTICLE
Wei Wen, Yuehua Li, Xi Cao, Yanyan Li, Ziyi Liu, Zhuoqi Tang, Liming Xie, Rongfang He
BACKGROUND: NUDCD1 (NudC Domain Containing 1) performs an essential function in biological processes such as cell progression, migration, cell cycle, and intracellular material transport. Many solid tumors express it highly, which is a prospective biomarker and therapeutic approach. However, the expression and clinical importance of NUDCD1 across breast cancer is unclear. METHODS: The expressions of NUDCD1 in breast cancers and normal breast tissues were studied utilizing the TIMER database and immunohistochemical analysis...
March 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38548519/exploring-the-oncogenic-potential-of-timm8a-a-crucial-factor-in-breast-cancer-tumorigenesis
#14
JOURNAL ARTICLE
Yili Chi, Suzita Hirachan, Yuying Zhou, Adheesh Bhandari
BACKGROUND: Female breast cancer has become the world's most common malignant tumor, displacing lung malignancy, and the incidence of malignant tumors has increased continuously in recent decades. However, the underlying molecular mechanisms of breast tumorigenesis have not been fully elucidated. By consulting the literature, we discovered that the TIMM8A gene could affect oxidative stress and apoptosis in patients with Mohr-Tranebjærg syndrome. However, the biological function of TIMM8A has yet to be explored...
March 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38548516/quality-of-life-outcomes-associated-with-optimization-of-treatment-by-omitting-radiotherapy-in-early-breast-cancer
#15
JOURNAL ARTICLE
Lesley Stafford, Michelle Sinclair, Phyllis Butow, Janemary Hughes, Allan Park, Leslie Gilham, Allison Rose, G Bruce Mann
PURPOSE: Improved prognosis of early breast cancer (EBC) has created opportunities for treatment optimization but reducing morbidity should not inadvertently compromise quality of life (QoL). PROSPECT1 used pre-operative MRI and pathology findings to identify women suitable for radiotherapy (RT) omission following breast conserving surgery. We retrospectively explored the association between de-escalation by omission of RT and QoL in women with EBC. MATERIALS AND METHODS: Three groups were recruited: PROSPECT participants who omitted RT following preoperative MRI (A); participants who received RT following preoperative MRI (B); and women who received usual care - No MRI, received RT (C)...
March 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38580572/parp-inhibitor-for-neoadjuvant-therapy-in-her2-negative-breast-cancer-a-systematic-review-and-meta-analysis-of-efficacy-and-safety
#16
REVIEW
Xiaomeng Jia, Kainan Wang, Qiping Zhuo, Zuowei Zhao, Man Li
Poly-ADP ribose polymerase inhibitor (PARPi) is approved for HER2-negative advanced breast cancer with BRCA1/2 mutation. In recent years, many studies have explored the application of PARPi in neoadjuvant therapy, but failed to reach a unified conclusion. PubMed, Clinicaltrials.gov, Cochrane CENTRAL, Embase, and key oncological meetings for trials were searched for studies reporting neoadjuvant regimens with PARPi in HER2-negative breast cancer. Pathological complete response (pCR), residual cancer burden (RCB), breast-conservation surgery rate (BCSR), clinical response, and adverse events were extracted and pooled in a meta-analysis using the Mantel Haenszel random/fixed effects model...
March 2, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38565462/short-term-effects-of-dry-heat-treatment-fluidotherapy-in-the-management-of-breast-cancer-related-lymphedema-a-randomized-controlled-study
#17
JOURNAL ARTICLE
Burcu Duyur Çakıt, Seçil Pervane Vural
BACKGROUND: To investigate whether fluidotherapy added to complete decongestive therapy (CDT) would provide additional contribution to edema reduction in patients with breast cancer related lymphedema (BCRL). MATERIAL AND METHODS: Thirthy-two patients with unilateral BCRL were randomly divided into 2 groups: standard treatment with CDT only (Group 1) and CDT + fluidotherapy (Group 2). All patients underwent phase 1 CDT, which included manual lymphatic drainage, multilayer bandaging, supervised exercises and skin care for a total of 15 sessions, 5 times a week for 3 weeks...
March 1, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38548517/photoacoustic-imaging-radiomics-to-identify-breast-cancer-in-bi-rads-4-or-5-lesions
#18
JOURNAL ARTICLE
Guoqiu Li, Zhibin Huang, Hui Luo, Hongtian Tian, Zhimin Ding, Yaohong Deng, Jinfeng Xu, Huaiyu Wu, Fajin Dong
OBJECTIVES: To develop a nomogram based on photoacoustic imaging (PAI) radiomics and BI-RADs to identify breast cancer (BC) in BI-RADS 4 or 5 lesions detected by ultrasound (US). METHODS: In this retrospective study, 119 females with 119 breast lesions at US and PAI examination were included (January 2022 to December 2022). Patients were divided into the training set (n = 83) or testing set (n = 36) to develop a nomogram to identify BC in BI-RADS 4 or 5 lesions...
February 29, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38548518/-18-f-fes-pet-ct-for-post-cryoablation-evaluation-of-breast-cancer
#19
EDITORIAL
Celina Duran, Robert C Ward, Elizabeth H Dibble
No abstract text is available yet for this article.
February 28, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38538518/independent-validation-of-the-brenda-score-breast-cancer-prognosis-prediction-tool-in-chinese-patients
#20
JOURNAL ARTICLE
Shao Ma, Yunxia Liu, Peng Gao, Rong Ma
BACKGROUND: The BRENDA-Score was developed and used to predict the prognosis of patients with breast cancer (BC). This study was performed to validate the use of this tool in Chinese patients with primary invasive BC patients. METHODS: Patients underwent surgery for BC from January 2009 to December 2016. Discrimination was assessed by the area under the receiver operating characteristic (ROC) curve (AUC). Calibrations were assessed by comparing predicted and observed 5-year and 10-year metastasis-free survival (MFS) in the overall cohort and patient subgroups...
February 28, 2024: Clinical Breast Cancer
journal
journal
34827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.